Inhibition of endothelial progenitor cell glycogen synthase kinase-3β results in attenuated neointima formation and enhanced re-endothelialization after arterial injury

Cardiovascular Research

Volumn 83, Issue 1, 2009, Pages 16-23

  Hibbert, Benjamin ^a   Ma, Xiaoli ^a   Pourdjabbar, Ali ^a   Holm, Erik ^a   Rayner, Katey ^a   Chen, Yong Xiang ^a   Sun, Jiangfeng ^a   Filion, Lionel ^b   O'Brien, Edward R ^a  

^a UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Endothelial progenitor cells; Glycogen synthase kinase; Integrin; Neointima; Re endothelialization; Vascular endothelial growth factor

Indexed keywords

ALPHA4 INTEGRIN; GLYCOGEN SYNTHASE KINASE 3BETA; MESSENGER RNA; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTERY INJURY; ARTERY INTIMA; ARTERY MEDIA; ARTICLE; CELL ADHESION; CELL SURVIVAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; ENDOTHELIUM CELL; ENZYME INHIBITION; FEMORAL ARTERY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STEM CELL;

ANIMALS; APOPTOSIS; ARTERIES; CELL ADHESION; CELL SURVIVAL; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; GLYCOGEN SYNTHASE KINASE 3; HOMEOSTASIS; HUMANS; INTEGRIN ALPHA4; MESENCHYMAL STEM CELLS; MICE; MODELS, ANIMAL; NEOVASCULARIZATION, PATHOLOGIC; THIAZOLES; TUNICA INTIMA; UREA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 67649303331     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvp156     Document Type: Article

References (28)

1. Ross R. Atherosclerosis-an inflammatory disease. N Eng J Med 1999;340:115-126.
2. Pasterkamp G, de Kleijn D, Borst C. Arterial remodeling in atherosclerosis, restenosis and after alteration of blood flow: potential mechanisms and clinical implications. Cardiovasc Res 2000;45:843- 852.
3. Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003;348:593-600.
4. Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link A et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 2005;353:999-1007.
5. Werner N, Junk S, Laufs U, Link A, Walenta K, Bohm M et al. Intravenous transfusion of endothelial progenitor cells reduces neointima formation after vascular injury. Circ Res 2003;93:e17-e24.
6. Schachinger V, Erbs S, Elsasser A, Haberbosch W, Hambrecht R, Holschermann H et al. Improved clinical outcome after intracoronary administration of bone-marrow-derived progenitor cells in acute myocardial infarction: final 1-year results of the REPAIR-AMI trial. Eur Heart J 2006;27:2775-2783.
7. Zampetaki A, Kirton JP, Xu Q. Vascular repair by endothelial progenitor cells. Cardiovasc Res 2008;78:413-421.
8. Walter DH, Rittig K, Bahlmann FH, Kirchmair R, Silver M, Murayama T et al. Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. Circulation 2002;105:3017-3024.
9. Kong D, Melo LG, Gnecchi M, Zhang L, Mostoslavsky G, Liew CC et al. Cytokine-induced mobilization of circulating endothelial progenitor cells enhances repair of injured arteries. Circulation 2004;110:2039-2046.
10. Aoki J, Serruys PW, van BH, Ong AT, McFadden EP, Sianos G et al. Endothelial progenitor cell capture by stents coated with antibody against CD34: the HEALING-FIM (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth-First In Man) Registry. J Am Coll Cardiol 2005;45:1574- 1579.
11. Co M, Tay E, Lee CH, Poh KK, Low A, Lim J et al. Use of endothelial progenitor cell capture stent (Genous Bio-Engineered R Stent) during primary percutaneous coronary intervention in acute myocardial infarction: intermediate- to long-term clinical follow-up. Am Heart J 2008;155:128-132.
12. Heeschen C, Lehmann R, Honold J, Assmus B, Aicher A, Walter DH et al. Profoundly reduced neovascularization capacity of bone marrow mononuclear cells derived from patients with chronic ischemic heart disease. Circulation 2004;109:1615-1622.
13. Yost C, Torres M, Miller JR, Huang E, Kimelman D, Moon RT. The axis-inducing activity, stability, and subcellular distribution of betacatenin is regulated in Xenopus embryos by glycogen synthase kinase 3. Genes Dev 1996;10:1443-1454.
14. Trowbridge JJ, Xenocostas A, Moon RT, Bhatia M. Glycogen synthase kinase-3 is an in vivo regulator of hematopoietic stem cell repopulation. Nat Med 2006;12:89-98.
15. Aicher A, Kollet O, Heeschen C, Liebner S, Urbich C, Ihling C et al. The Wnt antagonist Dickkopf-1 mobilizes vasculogenic progenitor cells via activation of the bone marrow endosteal stem cell niche. Circ Res 2008;103:796-803.
16. Hibbert B, Chen YX, O'Brien ER. c-kit-immunopositive vascular progenitor cells populate human coronary in-stent restenosis but not primary atherosclerotic lesions. Am J Physiol Heart Circ Physiol 2004;287:H518-H524.
17. Hirschi KK, Ingram DA, Yoder MC. Assessing identity, phenotype, and fate of endothelial progenitor cells. Arterioscler Thromb Vasc Biol 2008;28:1584-1595.
18. Eggermann J, Kliche S, Jarmy G, Hoffmann K, Mayr-Beyrle U, Debatin KM et al. Endothelial progenitor cell culture and differentiation in vitro: a methodological comparison using human umbilical cord blood. Cardiovasc Res 2003;58:478-486.
19. Sata M, Maejima Y, Adachi F, Fukino K, Saiura A, Sugiura S et al. A mouse model of vascular injury that induces rapid onset of medial cell apoptosis followed by reproducible neointimal hyperplasia. J Mol Cell Cardiol 2000;32:2097-2104.
20. Hall JL, Chatham JC, Eldar-Finkelman H, Gibbons GH. Upregulation of glucose metabolism during intimal lesion formation is coupled to the inhibition of vascular smooth muscle cell apoptosis. Role of GSK3beta. Diabetes 2001;50:1171-1179.
21. Seeger FH, Tonn T, Krzossok N, Zeiher AM, Dimmeler S. Cell isolation procedures matter: a comparison of different isolation protocols of bone marrow mononuclear cells used for cell therapy in patients with acute myocardial infarction. Eur Heart J 2007;28:766-772.
22. Hibbert B, Olsen S, O'Brien ER. Involvement of progenitor cells in vascular repair. Trends Cardiovasc Med 2003;13:322-326.
23. George J, Herz I, Goldstein E, Abashidze S, Deutch V, Finkelstein A et al. Number and adhesive properties of circulating endothelial progenitor cells in patients with in-stent restenosis. Arterioscler Thromb Vasc Biol 2003;23:57e-60.
24. Kim HS, Skurk C, Thomas SR, Bialik A, Suhara T, Kureishi Y et al. Regulation of angiogenesis by glycogen synthase kinase-3beta. J Biol Chem 2002;277:41888-41896.
25. Choi JH, Hur J, Yoon CH, Kim JH, Lee CS, Youn SW et al. Augmentation of therapeutic angiogenesis using genetically modified human endothelial progenitor cells with altered glycogen synthase kinase-3beta activity. J Biol Chem 2004;279:49430-49438.
26. Ma X, O'Brien ER. Antagonism of the alpha-4 integrin subunit attenuates the acute inflammatory response to stent implantation yet is insufficient to prevent late intimal formation. J Leukocyte Biol 2004;75:1016- 1021.
27. Yoshioka T, Takahashi M, Shiba Y, Suzuki C, Morimoto H, Izawa A et al. Granulocyte colony-stimulating factor (G-CSF) accelerates reendothelialization and reduces neointimal formation after vascular injury in mice. Cardiovasc Res 2006;70:61-69.
28. Yao YY, Yin H, Shen B, Smith RS Jr, Liu Y, Gao L et al. Tissue kallikrein promotes neovascularization and improves cardiac function by the Akt-glycogen synthase kinase-3beta pathway. Cardiovasc Res 2008;80:354-364.